Dermatology - Page 7
The MD Magazine Dermatology - Page 7 specialty page provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

Sponsored

Early Subcutaneous Allergen Immunotherapy Works for Certain Patients
Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.
The stem cells can be turned into brain cells in laboratories, which can give scientists a better understanding of the genes and characteristics of brain cells that bipolar disorder patients have.
Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.
The issue of when to use eczema and when atopic dermatitis has thrown a wrench into data-mining machinations.
Childhood atopic dermatitis (AD) usually resolves before adulthood, a meta-analysis of cases showed. Those patients who did see their AD persist were more likely to be female, to have been older at onset, and to have relatively severe AD.
An early clinical trial of a topical preparation of tofacitinib, a janus kinase (JAK) inhibitor, demonstrated that it improved symptoms of atopic dermatitis (AD) and was well tolerated.
Analysis of patient records from Denmark and Iceland found that obese psoriatic arthritis patients responded less than their lighter counterparts to tumor necrosis factor inhibitors (TNFIs) and that they used such medications for shorter periods of time.
What is someone to do when their father wants them to be a physician, like him, but their mother doesn't want them to have the long hours lifestyle? Michael Sherling, MD, of Palm Beach Dermatology, and chief medical officer and co-founder of Modernizing Medicine, was able to make both work.
The drug, a fully human monoclonal antibody that has impressed equally in asthma and atopic dermatitis trials, may be approved for market as soon as March of 2017.

Most Popular in Dermatology - Page 7

Recent Published Journal

@MDMagazine

$vacMongoViewPlus$ $vAR$